{"id":"a-101-solution-45","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site erythema"},{"rate":null,"effect":"Application site pain or burning"},{"rate":null,"effect":"Hyperpigmentation"},{"rate":null,"effect":"Hypopigmentation"}]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"A-101 is a proprietary formulation containing high-concentration hydrogen peroxide and other active ingredients designed for direct application to skin lesions. It works by inducing controlled chemical destruction of the target tissue, leading to lesion removal. The solution is applied topically in a controlled manner to minimize damage to surrounding healthy skin.","oneSentence":"A-101 Solution 45 is a topical keratolytic agent that chemically destroys skin lesions through controlled application of a caustic formulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:27:51.658Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seborrheic keratosis"},{"name":"Actinic keratosis"}]},"trialDetails":[{"nctId":"NCT03812510","phase":"PHASE3","title":"Safety Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2019-02-07","conditions":"Common Wart","enrollment":426},{"nctId":"NCT03691831","phase":"PHASE3","title":"A Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-09-13","conditions":"Common Wart","enrollment":502},{"nctId":"NCT03687372","phase":"PHASE3","title":"Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2018-09-17","conditions":"Common Wart","enrollment":503},{"nctId":"NCT02669862","phase":"PHASE2","title":"A Study of A-101 Solution in Subjects With Common Warts.","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2015-12-21","conditions":"Common Warts","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"A-101 Solution 45","genericName":"A-101 Solution 45","companyName":"Aclaris Therapeutics, Inc.","companyId":"aclaris-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A-101 Solution 45 is a topical keratolytic agent that chemically destroys skin lesions through controlled application of a caustic formulation. Used for Seborrheic keratosis, Actinic keratosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}